tislelizumab:

Mingxing Wang1, Qingming Sun1, Wanhui Dong1

  • 1Department of Medical Oncology, Lu'an Hospital of Traditional Chinese Medicine Affiliated To Anhui University of Chinese Medicine, Lu'an, China.

Frontiers in oncology
|December 16, 2024
PubMed
概括

作为PD-1抑制剂的tislelizumab可以引起罕见的免疫相关不良事件. 本病例报告详细介绍了皮性食道炎,一种新奇的副作用,成功地用皮质类固醇治疗.